phase I clinical development
Critical Success Factors in Patient Safety Strategies
June 14 by Gabriele DallmannIn this Pharma IQ interview Nabil Al-Tawil, Principal Investigator of the Phase I Unit at Karolinska University Hospital, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation...
Troubleshooting Biomarker Development Strategies
June 09 by Gabriele DallmannIn this Pharma IQ interview Kristof Vercruysse, Director Clinical Operations at Ablynx, speaks to Dr. Gabriele Dallmann, CEO of Pharmatching GmbH, about innovation in phase I clinical developme...
Challenges and Benefits of Patient-Based Phase I Trials
May 05 by Pharma IQPharma IQ held a Q&A session with Dr. James Dow, Director of Clinical Pharmacology & DMPK, (OSI) Prosidion to gain a few insights into phase I clinical development and patient-bas...
Improving Biomarker Development Work Flow in Phase I Clinical Development
September 07 by Helen WinsorReto Ossola, Group Leader for Biomarker Research at Biognosys, joins Pharma IQ to discuss the main challenges in biomarker development and some key ways to address these. Ossola offers some best...
Streamlining the Development and Validation Process in Discovery to Phase I Clinical Development
September 05 by Pharma IQReto Ossola, Group Leader for Biomarket Research at Biognosys, joins Helen Winsor from Pharma IQ, to discuss phase I clinical development. He outlines where he sees the main challenges in biomarker de...
